The “New Ozempic” falls short.

If you wondered why the NVO stock (see above) was down almost 20% yesterday, look no further. “[Its] experimental diabetes and weight-loss drug CagriSema fell short of expectations. The drug did not achieve the projected 25% average weight loss anticipated by the company and analysts. Instead, patients in the phase 3 clinical trial lost an average of 22.7% of their body weight after 68 weeks on the medication.” ~ learn more

Leave a Reply

Your email address will not be published. Required fields are marked *